Clinical Trials Logo

Erythema Chronicum Migrans clinical trials

View clinical trials related to Erythema Chronicum Migrans.

Filter by:

NCT ID: NCT06451913 Not yet recruiting - Clinical trials for Erythema Migrans of Lyme Disease

Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in the Context of Erythema Migrans (Early Skin Form of Lyme Borreliosis))

SUBLYME
Start date: June 2024
Phase: Phase 4
Study type: Interventional

The aim of this study is to assess the effect of Saccharomyces boulardii CNCM I-745 on gut microbiota in patients undergoing antibiotic therapy (in the context of erythema migrans (early skin form of Lyme borreliosis)).

NCT ID: NCT03980015 Completed - Erythema Migrans Clinical Trials

Inflammatory Responses in Solitary and Multiple Erythema Migrans

Start date: June 1, 2006
Phase:
Study type: Observational

The investigators will evaluate differences in host immune responses (levels of cytokines and chemokines, representative of innate, Th1, and Th17 immune responses) in acute sera from adult patients with solitary or multiple erythema migrans.

NCT ID: NCT03966014 Recruiting - Erythema Migrans Clinical Trials

Different Amoxicillin Treatment Regimens in Erythema Migrans Patients

Start date: June 1, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the efficacy of different amoxicilline treatment regimens in patients with erythema migrans.

NCT ID: NCT03956212 Completed - Erythema Migrans Clinical Trials

Inflammatory Mediators in Erythema Migrans

Start date: June 1, 2017
Phase: N/A
Study type: Interventional

The main objective of this study is to characterize the inflammatory proteins, gene polymorphisms, and transcriptome profiles in patients with erythema migrans to gain better insight into pathogenesis of early Lyme borreliosis and to define new immune modulators that could serve as biomarkers of disease activity.

NCT ID: NCT03584919 Completed - Clinical trials for Erythema Chronicum Migrans

Comparison of Doxycycline and Cefuroxime Axetil in Erythema Migrans

Start date: June 1, 2006
Phase: N/A
Study type: Interventional

A European, prospective clinical trial in which doxycycline and cefuroxime axetil were compared in the treatment of adult patients with erythema migrans included a control group to address this question. Evaluations of patients were conducted at baseline, 14 days and 2, 6, and 12 months after enrollment. Control subjects were evaluated at baseline and at 6 and 12 months. Subjective complaints that newly developed or intensified since the onset of erythema migrans or since the date of enrollment for controls were referred to as "new or increased symptoms"(NOIS).

NCT ID: NCT03505879 Completed - Lyme Disease Clinical Trials

Next Generation Sequencing Detection of Lyme Disease

Start date: July 24, 2018
Phase:
Study type: Observational

Next Generation Sequencing is capable of sequencing millions of small strands of DNA from a single blood sample, potentially improving its sensitivity compared to PCR testing, which only detects predetermined larger strands of DNA. We will test the ability of NGS to detect Borrelia burgdorferi DNA in the blood of pediatric patients with Lyme disease. We will conduct an observational study of NGS testing on pediatric patients at all stages of Lyme disease. Study involvement will require a single study visit for clinical data collection and blood draw. We will enroll patients at all phases of suspected Lyme disease, collect clinically relevant information, and test for Lyme disease using Next Generation Sequencing and standard Lyme serologic testing. If the patient has multiple erythema migrans, Lyme meningitis, facial nerve palsy, arthritis, or carditis, a B. burgdorferi serum PCR will also be sent. Enrollment and Next Generation Sequencing blood draw will occur before or up to 24 hours after the first dose of antibiotics is administered. We will also study the impact of antibiotics on NGS testing by running the test 6-24 hours after antibiotics are started among a small subset of patients with a multiple erythema migrans rash. Collected data will be analyzed with basic descriptive statistics.

NCT ID: NCT03462329 Recruiting - Erythema Migrans Clinical Trials

Patient's Pretreatment Expectations About Post-Lyme Symptoms

Start date: June 1, 2018
Phase: N/A
Study type: Interventional

The investigators will focus on pretreatment expectations of patients with early Lyme disease manifested as erythema migrans with the aim of assessing the association between pretreatment expectations quantified with a questionnaire and treatment outcome quantified with the presence of post-Lyme symptoms. Furthermore, the investigators will compare the prevalence of nonspecific symptoms among patients and among age-matched controls without a history of Lyme borreliosis.

NCT ID: NCT03371563 Completed - Lyme Disease Clinical Trials

Erythema Migrans in Elderly

Start date: January 1, 2006
Phase:
Study type: Observational [Patient Registry]

The investigators will focus on elderly patients with early Lyme borreliosis with the aim of assessing clinical course, serological response and treatment outcome of the disease as compared to younger adults. Furthermore, the investigators will compare the prevalence of nonspecific symptoms among patients and among age-matched controls without a history of Lyme borreliosis.

NCT ID: NCT03337932 Recruiting - Clinical trials for Erythema Chronicum Migrans

Duration of Doxycycline Treatment in MEM Patients

Start date: May 1, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the efficacy of 7-day versus 14-day doxycycline treatment in patients with multiple erythema migrans.

NCT ID: NCT03238274 Completed - Clinical trials for Borrelia; Infection, Burgdorferi (Erythema Chronicum Migrans)

Sofia 2 Lyme FIA Whole Blood Clinical Study

Start date: June 6, 2017
Phase:
Study type: Observational

The objective of this study is to demonstrate the clinical performance of the Sofia® 2 analyzer and Sofia Lyme FIA test in the CLIA waived test environment in comparison to Comparator Method(s) and/or an FDA cleared predicate test(s) using matched finger-stick, whole blood and serum from symptomatic subjects.